Design Therapeutics, Inc. DSGN R2KR3KPHARMA
Company Overview
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +88.93% |
| 6 Months: | -18.28% |
| 3 Months: | -13.80% |
| 1 Month: | -16.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 35.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DSGN Design Therapeutics, Inc. R2KR3KPHARMA | 10.24 | -8.68 | $640.84M | 0.00% | -37.28% | -34.13% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 31.00K | 20.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -623.00K | -1.46M | -2.38M | -5.68M | -7.69M | -11.34M | -13.37M | -15.64M | -19.19M | -21.65M | -22.60M | -18.82M | -14.40M | -15.04M | -16.25M | -20.42M | -21.57M | -19.31M | -19.71M | -22.18M |
| Net Income | -663.00K | -1.44M | -2.32M | -5.51M | -7.64M | -11.32M | -13.27M | -15.00M | -17.70M | -19.29M | -19.94M | -15.79M | -11.11M | -11.79M | -13.04M | -17.71M | -19.08M | -17.00M | -17.64M | -20.16M |
| Diluted EPS | - | - | - | - | -0.14 | -0.21 | -0.24 | -0.27 | -0.32 | -0.35 | -0.36 | -0.28 | -0.20 | -0.21 | -0.23 | -0.31 | -0.34 | -0.30 | -0.29 | -0.32 |
| R&D Expense | 377.00K | 1.06M | 1.91M | 3.88M | 5.03M | 8.54M | 8.76M | 11.29M | 14.30M | 15.73M | 17.06M | 13.26M | 9.80M | 10.52M | 11.88M | 15.38M | 15.74M | 14.59M | 14.38M | 16.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 226.00K | - | - | - | 0 | 0 |
| Operating Income | -8.33M | -35.83M | -67.59M | -78.19M | -62.38M | -79.47M |
| Net Income | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M |
| Diluted EPS | - | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 |
| R&D Expense | 6.06M | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 36.52M | 390.56M | 341.14M | 289.64M | 252.09M | 226.20M |
| Total Equity | -3.64M | -11.31M | 382.13M | 327.31M | 277.69M | 242.10M | 212.50M |
| Cash & Equivalents | - | 2.38M | 298.57M | 26.50M | 21.20M | 22.56M | 16.86M |
| Total Liabilities | - | 2.48M | 8.43M | 13.83M | 11.96M | 10.00M | 13.70M |
| Current Liabilities | - | 2.33M | 5.28M | 10.78M | 9.62M | 8.46M | 13.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.67M | -29.38M | -51.32M | -58.56M | -43.10M | -54.36M |
| Investing Cash Flow | -33.56M | -53.64M | -220.99M | 52.54M | 43.95M | 22.91M |
| Financing Cash Flow | 44.53M | 379.21M | 235.00K | 724.00K | 513.00K | 25.74M |
| Capital Expenditure | -76.00K | -1.54M | -918.00K | -256.00K | -340.00K | -193.00K |
| Free Cash Flow | -8.74M | -30.91M | -52.23M | -58.82M | -43.45M | -54.55M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -3,685.8% | - | - | - | - | - |
| Net Margin % | -3,663.7% | - | - | - | - | - |
| ROE % | 73.2% | -9.3% | -19.3% | -24.1% | -20.5% | -32.8% |
| ROCE % | -24.4% | -9.3% | -20.5% | -27.9% | -25.6% | -37.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SR One Capital Management, LP | 10.43% | 6.53M | $76.03M |
| 2 | Logos Global Management LP | 4.79% | 3.00M | $34.95M |
| 3 | Baker Bros. Advisors, LP | 4.28% | 2.68M | $31.20M |
| 4 | Blackrock Inc. | 4.25% | 2.66M | $30.99M |
| 5 | Driehaus Capital Management, LLC | 4.25% | 2.66M | $31.00M |
| 6 | Point72 Asset Management, L.P. | 3.78% | 2.37M | $27.57M |
| 7 | Trails Edge Capital Partners, LP | 3.20% | 2.00M | $23.31M |
| 8 | Frazier Life Sciences Management, L.P. | 2.89% | 1.81M | $21.08M |
| 9 | Vivo Capital, LLC | 2.58% | 1.61M | $18.79M |
| 10 | Vanguard Capital Management LLC | 2.51% | 1.57M | $18.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DSGN
DSGN Dec 2026 25.000 call (DSGN261218C00025000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE43TTdydHdJS1pSX1VJZHpMdlVsRGFkejFlX19sWS0xMXJNYko0X21yTFp5ZHlJZnhCSmNkTHVRSHVOUHRiTThlYkxNM0dBWkZPdkhnczBrdHpSSDAyY09FQk9QcURzdw?oc=5" target="_blank">DSGN Dec 2026 25.000 call (DS…
Understanding Momentum Shifts in (DSGN) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQcjZodnE1UVdyZE56VC1zeHpJalJJNDRlNEF2V2JzaTNXMlpjREFCYnZIZVdZUjNtSW02NDJjX3NxM2xqYXRtZHdFOW5rNGt4bEM4ZTZua3lBRVMxejhhcXp2b1lhSFdqUDFOdW9wc0lnQXhSbUlBelh0U0Y2WlBZZXd4MVVmT1VFU29zbV…
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUy1fNWROYzU1NlpEdTB2eVRST18tVTVvZ1RtUVFxbHFsSm5nZUFOeVcxbUVlRGMxWE16T1dLRE1idzZRUUFJWE51TVVLLVlpUm9wNHR6cWV6Zm9vQ3pDeERKaHdQWUdYRy1VMHpHRzFNX3VUMU1BeFQ4TGRsbzRxazFEZHVSZ3A1TWJsY0…
DSGN Nov 2026 19.000 call (DSGN261120C00019000) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFB0YmF2VGI5NEVLdVpDOGN2eURfbTlkN2JqR0VFYlZYaXREUGdnOHlsQkNNX3lKU08tdnlPdXZHSkJ6ZzNUckRaRUNRM05xLTFaYmh3Uld5VGxjQnpkbHhaMnM0MnN5Zw?oc=5" target="_blank">DSGN Nov 2026 19.000 call (DS…
Fair Isaac or Cadence Design Systems: Which Stock Has More Upside? - Trefis
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNV3BiT2hWNEE1cEU3dDREbGVNUFlHZlFrZE5kcnl3QUhNRTZ1NHZhRFpXbks3RTE2aWFVOUppMVlCLWVtSkhYZTJwZ0hnWDVJWW5EV2ZGeHRfOU42bHFXTTdMam1jdm53M0hkZ1JWWXZrTFM1X3gwbHlKVzgwOHJoZUEzRmlFWXhNVWZfcj…
The Market May Be Underestimating This AI Chip-Design Stock - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQNlAwNTltY2hGeXVpbDJ4SHBhRTh4MW9rVEduLVpyWnNDVUExU1VxVFlhWUNoNkdseEhreXdmcjA0ZE5USy0zc2VrQ1NkRmpoNW9BZkltTC1HQzRpT1hUeUwtcVF4dDh6VDZIR0xGU3ZOWlRkMnRvNENsdnVEN21oUnRIalgydV9EYzdCY1…
DSGN — Frequently Asked Questions
What is the current share price of Design Therapeutics, Inc. (DSGN)?
As of 2026-10-23 16:27 PDT, Design Therapeutics, Inc. (DSGN) trades at $10.24 on NasdaqGS. Its 52-week range is $4.79 to $15.94.
What is the market capitalisation of DSGN?
Design Therapeutics, Inc. (DSGN) has a market capitalisation of $640.84M on NasdaqGS.
What is the P/E ratio of DSGN?
DSGN trades at a trailing price-to-earnings (P/E) ratio of -8.68. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 3.61.
What is the return on equity (ROE) of DSGN?
DSGN has a return on equity (ROE) of -34.13%. Its return on capital employed (ROCE) is -37.28%.
Is DSGN a good stock to buy?
This page provides a data-driven analysis of Design Therapeutics, Inc. (DSGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.